Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 8;15(682):eabn5993.
doi: 10.1126/scitranslmed.abn5993. Epub 2023 Feb 8.

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria

Affiliations

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria

Dennis O Odera et al. Sci Transl Med. .

Abstract

Natural killer (NK) cells are potent immune effectors that can be activated via antibody-mediated Fc receptor engagement. Using multiparameter flow cytometry, we found that NK cells degranulate and release IFN-γ upon stimulation with antibody-opsonized Plasmodium falciparum merozoites. Antibody-dependent NK (Ab-NK) activity was largely strain transcending and enhanced invasion inhibition into erythrocytes. Ab-NK was associated with the successful control of parasitemia after experimental malaria challenge in African adults. In an independent cohort study in children, Ab-NK increased with age, was boosted by concurrent P. falciparum infections, and was associated with a lower risk of clinical episodes of malaria. Nine of the 14 vaccine candidates tested induced Ab-NK, including some less well-characterized antigens: P41, P113, MSP11, RHOPH3, and Pf_11363200. These data highlight an important role of Ab-NK activity in immunity against malaria and provide a potential mechanism for evaluating vaccine candidates.

PubMed Disclaimer

Conflict of interest statement

Competing interests: B.K.L.S., Y.A., P.F.B., S.L.H., E.R.J., and T.L.R. are salaried, full-time employees of Sanaria Inc., the manufacturer of Sanaria PfSPZ Challenge. Thus, all authors associated with Sanaria Inc. have potential conflicts of interest. All other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1. Anti-merozoite antibodies activate NK cells.
(A) NK cell degranulation and IFN-γ production were measured by CD107a surface and intracellular staining, respectively. Merozoites were opsonized with a pool of malaria-exposed (n = 4) or naïve plasma (n = 4), with PHA/ionomycin included as a positive control. Malaria-exposed plasma samples from adults in Junju county were used to optimize the assay. Data are from four independent experiments and show the median with a 95% confidence interval (95% CI). Differences between groups are compared using the Kruskal-Wallis test. (B) NK cell degranulation upon stimulation with merozoites opsonized with individual plasma samples from malaria-exposed Junju adults (n = 30). PBMCs were collected on three separate days. The graph shows the pairwise correlation of the percentage (%) of NK cells degranulating after coincubation with merozoites opsonized with malaria-exposed plasma between independent experiments conducted on 3 separate days. The red dots show the correlation between experiments conducted on day 1 versus day 2 (experiment 2). In contrast, the blue dots show the correlation between experiments on day 1 versus day 3 (experiment 3). (C and D) Representative flow plots of NK cells incubated with merozoites in the presence of malaria-exposed or malaria-naïve plasma are shown. P. falciparum merozoites opsonized with plasma from individual malaria-exposed adults (red circles, n = 20) or malaria-naïve plasma (blue circles, n = 4) were coincubated with donor NK cells. An additional pool of hyperimmune sera (PHIS) was included as a positive control (brown circles, n = 4). This pool was prepared from Junju adults with high ELISA responses against parasite schizont lysate from the 3D7 strain of P. falciparum. Error bars represent 95% CI of the median values; Kruskal-Wallis test. (E) Pairwise correlation between the proportion of IFN-γ–secreting or IFN-γ–degranulating (CD107a+) NK cells activated by opsonized P. falciparum 3D7 merozoites and merozoite ELISA quantifying total IgG responses (OD; n = 142). (F) Spearman’s correlation heatmap between the proportion of NK cells degranulating upon activation by opsonized merozoites from five P. falciparum strains of different geographical origins (n = 20). (G) Viable merozoites were coincubated with uninfected erythrocytes and test immunoglobulins (1.5 ng per well) in the presence or absence of donor NK cells. Data represent the median with 95% CIs of three independent experiments.
Fig. 2
Fig. 2. Antibody-mediated NK cell activity is associated with in vivo parasite growth.
Comparison of Ab-NK cell degranulation (A) and IFN-γ production (B) in treated (n = 56) versus nontreated (n = 86) volunteers. Bars represent 95% CI of the median values; Mann-Whitney test. Subgroup analysis of Ab-NK cell degranulation (C) and IFN-γ production (D) for treated volunteers who either developed fever (febrile, n = 26) or did not (nonfebrile, n = 30) and for untreated volunteers in whom parasites were either detected by PCR (PCR+, n = 53) or remained negative (PCR, n = 33). Bars represent 95% CI of the median values; Kruskal-Wallis with Dunn’s multiple comparisons test. Kaplan-Meier curves for the time to treatment for volunteers with a high (red) versus low (blue) Ab-NK cell degranulation (E) and IFN-γ production (F); log-rank test, P < 0.0001, n = 142.
Fig. 3
Fig. 3. Potential targets of antibodies that mediate Ab-NK.
(A) Antigen-specific Ab-NK cell degranulation from a subset of CHMI individuals (n = 10) against 14 unique recombinant P. falciparum merozoite antigens. The dashed line represents the cutoff value based on the mean plus 3 SDs of the tagged fragment (CD4 tag). Error bars represent 95% CI of the median (red line). (B) Heatmap of individual level antigen-specific Ab-NK cell degranulation from (A). Each row represents a single CHMI participant, and each column represents responses to a single recombinant merozoite surface–associated antigen. (C) Ab-NK cell degranulation against whole merozoite extract was associated with the breadth of antigen-specific recognition. Error bars represent 95% CI of the median (red line) n = 142; Kruskal-Wallis test. (D) The sum of antigen-specific Ab-NK cell degranulation against 14 unique recombinant merozoite antigens was correlated with NK cell degranulation against merozoites; Spearman’s correlation R = 0.80.
Fig. 4
Fig. 4. Antibody-mediated NK cell degranulation is associated with clinical protection in a prospective cohort study in Kenyan children.
(A) Comparison of Ab-NK cell degranulation (left) and IFN-γ production (right) in Junju children over or under 5 years of age. (B) Ab-NK response in children who had an active P. falciparum infection compared with those without. Error bars represent 95% CI of the median values; Mann-Whitney test (n = 293). (C) Antibody-mediated NK cell degranulation (left) and IFN-γ production (right) were correlated with the breadth of total IgG responses against recombinant MSP2, MSP3, and/or AMA-1. Error bars represent 95% CI of the median values; Kruskal-Wallis test with Dunn’s multiple comparisons test (n = 293). (D) Ab-NK cell degranulation and IFN-γ production were associated with clinical protection against symptomatic malaria in children. Ab-NK responses were categorized as high or low (blue) on the basis of a threshold (28); log-rank test, P = 0.001 (n = 293). Each dot represents a technical replicate.

Comment in

References

    1. WHO Malaria fact sheets. WHO malaria Fact sheets. WHO; 2021. [online] www.who.int/news-room/fact-sheets/detail/malaria www.who.int/news-room/fact-sheets/detail/malaria.
    1. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45. doi: 10.1016/S0140-6736(15)60721-8. - DOI - PMC - PubMed
    1. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28:51–60. - PubMed
    1. Cohen S, Mcgregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature. 1961;192:733–737. - PubMed
    1. Duncan CJA, Hill AVS, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy. Hum Vaccin Immunother. 2012;8:706–714. doi: 10.4161/hv.19712. - DOI - PMC - PubMed

Publication types